A practical primer on the analytical methods behind a research-peptide certificate of analysis: reverse-phase HPLC for purity, ESI-MS and MALDI-TOF for identity confirmation, and how to read the supporting chromatogram and spectrum. Research use only.
By PeptideDistro Editorial · Published 2026-04-27 · ~9 minute read
Two analytical questions sit at the center of every research-peptide lot release. The first is purity — what fraction of the material in the vial is the intended peptide, and what is the rest? The second is identity — does the molecule actually correspond to the sequence and modifications listed on the catalog page? Reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry (MS) answer those questions independently and complementarily. Reverse-phase HPLC separates molecules by hydrophobic retention behavior on a non-polar stationary phase; mass spectrometry weighs the molecules directly. A peptide that is a single sharp peak by HPLC could still be the wrong sequence if MS does not confirm the expected mass, and a peptide that confirms the right mass could still carry significant impurity if HPLC reveals a complex chromatogram. The combination is the standard.
This article walks through how each method is set up for research peptides, what the chromatogram and spectrum look like for a clean lot, and how a procurement reviewer should interpret the corresponding sections of a research-grade certificate of analysis. Method principles described here are aligned with the United States Pharmacopeia general chapters on chromatography and mass spectrometry (USP <621>; USP <1736>).
The default purity method for research peptides is reverse-phase HPLC on a C18 stationary phase. C18 columns immobilize an 18-carbon alkyl chain on porous silica or hybrid particles; peptides interact with the C18 layer through hydrophobic contacts on their non-polar side chains. A water/acetonitrile gradient containing a low concentration of trifluoroacetic acid (typically 0.1%) elutes peptides in order of increasing hydrophobicity. The peptide with the most polar amino-acid composition exits the column first; the peptide with the most non-polar composition exits last. Detection is most commonly UV absorbance at 220 nm, which catches the peptide bond, with secondary monitoring at 254 nm and 280 nm where appropriate (the latter picks up tryptophan and tyrosine residues).
Column dimensions for analytical-purity work are typically 4.6 × 150 mm or 4.6 × 250 mm with 3- or 5-µm particles, run at flow rates around 1 mL/min. Sub-2-µm UPLC columns shorten the run and sharpen the peaks but require higher pressure and instruments rated for that pressure. Gradient design depends on the peptide; a generic 5–95% acetonitrile gradient over 20–30 minutes is a reasonable starting point for unknown peptides, while characterized peptides typically use a narrower elution window centered on the known retention behavior.
What the procurement reviewer should look for in the chromatogram: a single dominant peak with reasonable peak shape (Gaussian-like, not severely tailing or fronting), a stable baseline, and no late-eluting hydrophobic impurities. Side peaks adjacent to the main peak are often deletion sequences (peptides missing one or more residues during solid-phase synthesis); peaks shifted by ±1 mass unit correspond to common deamidation or amidation isomers. Integration parameters used for the area-percent calculation should be clearly stated, and the lot-release threshold should be visible against the calculated purity result on the COA.
Solid-phase peptide synthesis introduces a known set of byproducts. The most common are deletion sequences, peptides in which one or more residues failed to couple during chain elongation. A peptide missing a single residue typically elutes earlier than the target on a C18 column (lower hydrophobicity from the loss) and shows up as a small shoulder peak or a closely-spaced satellite peak. Truncated sequences, in which capping reagents end the chain prematurely, also show shorter retention and lower mass.
Other recurring byproducts include oxidized methionine peaks (oxidation adds 16 Da and shifts polarity), deamidated asparagine or glutamine peaks (mass increases by 1 Da; the isoaspartate isomer often appears as a shoulder), and acetylation or trifluoroacetylation artifacts from incomplete deprotection. PEGylated peptides show a characteristic broad envelope rather than a single sharp peak because the PEG distribution itself spans a range of repeat units. Disulfide-bridged peptides can show free-thiol and oxidized-disulfide peaks if the cyclization step was not complete; the COA should state whether the cyclization is folded as designed.
ESI-MS is the method most commonly coupled to RP-HPLC for peptide identity confirmation. In ESI, the peptide is sprayed from a charged capillary at the mass spectrometer’s inlet; the mobile-phase eluent evaporates from the resulting micro-droplets, leaving multiply protonated peptide ions in the gas phase. The instrument records the mass-to-charge (m/z) of those ions, and a deconvolution step combines the charge-state envelope into a single observed mass.
Two pieces of information matter on a peptide ESI-MS spectrum. The first is the observed mass after deconvolution, which should match the expected mass of the listed sequence and modifications within the instrument’s established tolerance — typically <0.5 Da on a mid-range LC-MS for a 1–3 kDa peptide, much tighter on a high-resolution instrument. The second is the charge-state envelope itself: the +2/+3/+4 charge states that dominate for a small peptide should be present in the expected ratio, with no second envelope from a co-eluting impurity. Reviewers familiar with deconvolution math will sometimes request the raw charge-state spectrum in addition to the deconvoluted summary; PeptideDistro.com routes both on request as part of the batch documentation packet.
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) is the alternative identity method, particularly for higher-mass peptides, peptides that ionize poorly under ESI conditions, and high-throughput screening of fractions during purification. The peptide is co-crystallized with an organic matrix (typical matrices include α-cyano-4-hydroxycinnamic acid for peptides up to ~5 kDa, sinapinic acid for larger peptides) on a target plate; a UV laser pulses the matrix into the gas phase, ionizing the embedded peptide. The time-of-flight analyzer separates ions by flight time after acceleration, which is proportional to the square root of m/z.
MALDI-TOF spectra typically show a dominant singly charged [M+H]+ peak with a small [M+Na]+ adduct. Resolution is lower than on a high-resolution Orbitrap or FT-ICR instrument, and the typical mass tolerance for identity assignment is on the order of 50–500 ppm depending on instrument and calibration. MALDI-TOF is fast and minimally sample-consuming, which is why it dominates purification fraction screening. It is less well suited to PEGylated peptides because the matrix adduct distribution overlaps with the PEG-repeat envelope.
The chromatogram on the supporting record should be presented with a labeled x-axis (time in minutes), labeled y-axis (absorbance in mAU or normalized %), the gradient overlay or method conditions, integration windows for the main peak and any reported impurity peaks, and the calculated area-percent for each integrated region. The main peak should carry an identification — the catalog peptide name or its retention-marker reference — and the lot-release threshold should appear as a horizontal cue or in the method-summary block.
The MS spectrum should include a labeled m/z axis, a clearly identified [M+nH]n+ series for ESI or the [M+H]+ peak for MALDI, the deconvoluted observed mass (for ESI), the expected mass calculated from the listed sequence and modifications, and the deviation in absolute or relative units. For PEGylated, glycosylated, or fatty-acid-conjugated peptides, the supporting note should describe how the modifying group’s mass contribution was handled in the expected-mass calculation.
RP-HPLC purity and MS identity confirmation are the two analytical anchors of the PeptideDistro.com lot release process described in the quality assurance page. Each released lot is reviewed against the catalog entry on those two axes before the lot is staged for fulfillment to qualified accounts. Records are preserved against the buyer-account record and routed through the COA & document library on request. The same supporting chromatogram and spectrum that drive the lot-release decision are released to the buyer when documentation diligence requires it.
Continue reading: How to read a peptide certificate of analysis walks through the COA itself field by field. Wholesale peptide application checklist covers the qualified-buyer fields that travel alongside lot-record diligence. The quality assurance page documents the supplier-qualification, identity, and lot-release process behind every released lot, and the COA & document library is the routing point for lot-specific records and sample documentation packets.
Peptides span a wide hydrophobicity range and benefit from gradient elution on a non-polar C18 column with a water/acetonitrile gradient containing 0.1% TFA. The method resolves the target peptide from synthesis byproducts and integrates easily for area-percent purity reporting.
MALDI-TOF is useful for high-mass peptides, peptides that ionize poorly under ESI, and rapid screening of purification fractions. ESI-MS is preferred when isotope patterns and charge-state envelopes inform deconvolution and when LC-MS coupling with the purity assay is desired.
The COA is the lot-release summary; the chromatogram and spectrum are supporting data. PeptideDistro.com routes the underlying chromatogram and MS spectrum on request as part of the batch documentation packet so reviewers and audit teams can examine the analytical record behind the lot release.
This article is editorial reference for procurement and laboratory-workflow context. PeptideDistro.com does not provide medical advice, treatment claims, or dosage guidance. Lot-specific records are released to approved wholesale accounts only.